echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Xinda biology and adimab cooperate to develop therapeutic antibody

    Xinda biology and adimab cooperate to develop therapeutic antibody

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On August 20, Cinda biopharmaceutical (Suzhou) Co., Ltd

    announced that it has signed a development and commercialization plan for therapeutic antibody with adimab company of the United States

    The main terms of the scheme are: adimab develops therapeutic antibodies against targets selected by Cinda by using its antibody discovery and optimization platform

    If the development is successful, Cinda will be responsible for commercialization in China, and adimab will be responsible for commercialization in the United States, Europe and Japan

    Adimab can use yeast to synthesize therapeutic antibodies

    It has signed target discovery agreements with Merck, Roche, Novartis, Lilly, celgene, Genentech, Novo Nordisk, Gillette and GlaxoSmithKline

    Interestingly, two yeast engineering companies, adimab and glycofi

    Since the sale of glycofi to Merck for $400 million, the founding team left, established adimab, and got Google's venture capital

    Cinda bio pharmaceutical is invested by Fidelity Investment Group and Lilly pharmaceutical.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.